Mymetics Corp (MYMX)

[bow-tie]

Did anyone about the new trail with Imugene on Stomach Cancer:
https://immuno-oncologynews.com/2017/09/11/imugene-begins-phase-1b-and-2-trial-of-its-stomach-cancer-vaccine-her-vaxx/


HER-Vaxx was developed by researchers at the Medical University Vienna. Imugene partnered with Mymetics in 2014 to manufacture the drug.
“Our team is excited to be part of this important study and the search for effective new treatments for gastric cancer as there are limited options for patients,” Professor Christoph Zielinski, head of Medical University Vienna’s cancer program, said in a press release. He is principal investigator of the trial.
Imugene published encouraging preclinical-trial results of the HER-Vaxx’s ability to fight stomach cancer in the journal BMC Cancer. A new formulation of the drug generated a more potent immune response against cancer cells with Her2 protein, researchers said. Imugene will be using the formula in new clinical trials.
The Phase 1b/2 study (NCT02795988) has two parts. In the Phase 1b stage, patients will receive escalating doses of HER-Vaxx in combination with standard chemotherapy to determine an optimal dose.

https://clinicaltrials.gov/ct2/show/NCT02795988

Start Date: Aug 30th 2017
Est. Primary Completion Date: May 2018
Est. Study Completion Date: Sept 2018